Case Presentations

A Woman with Headache and Chest Pain
Theresa Pondok MD, PGY-3 Internal Medicine

A 34 y/o woman, with a past medical history significant
for asthma, newly diagnosed hypertension, and migraines,
presented to the emergency department with complaints
of sudden onset chest pain. She was an active young
woman, who up until the day of admission, had been able
to run several miles without chest pain or shortness of
breath. Symptoms began the morning of admission, when
the patient reported that she developed a migraine
heachache, with typical right-sided temporal pain. After
administering an injection of Sumatriptan, her headache
resolved. Soon thereafter, she noted 5/10 substernal chest
pressure occurring suddenly at rest, without radiation to
her arms or jaw. It was not associated with nausea,
vomiting, diaphoresis or shortness of breath. The patient
stated that she had never experienced this type of pain
before, which alarmed her enough to come to the
hospital. One sublingual nitroglycerin, given in the ED,
complete relieved her symptoms.
The patient’s medical history included hypertension,
asthma, Raynaud’s phenomena, and migraine headaches.
Hypertension was recently diagnosed, and well
controlled off medications with a strict regimen of diet
and exercise. Her asthma was stable with very occasional
use of an albuterol metered dose inhaler, and she stated
that she had never been intubated or required hospitalization for an exacerbation. Her Raynaud’s symptoms
occured in her fingertips intermittently during the winter
months for the past several years. Migraine headaches
were diagnosed 2 years prior, and she had been tried on
several different abortive therapies without success. The
Sumatriptan had just recently been prescribed, and this
instance represented her first use.
The patient had no surgical history. She denied alcohol,
tobacco, or intravenous drug abuse. She lived at home
with her husband and four children. Both parents were
still alive, her father with atrial fibrillation and her
mother with hypertension. There was no family history
of sudden death or coronary artery disease. The patient
took no regularly prescribed medications, only prn
albuterol MDI and sumatriptan injections. Her allergies
included aspirin and shellfish, both of which exacerbate
her asthma symptoms. Review of systems was positive
only for the chest pain described above, occasional
palpitations and migraine headaches.

On physical examination the patient was afebrile with a
pulse of 112, respirations of 20, blood pressure of
111/66, and O2 saturation of 100% on 3 liters nasal
cannula. She was alert and oriented, in no acute distress.
Her oropharynx was clear, and heart regular with a
normal S1 and S2, and no audible murmurs, gallops, or
rubs. There was no detectable jugular venous distention.
Lungs were clear, and her abdomen soft, nondistended,
and non-tender. No peripheral edema was appreciated.
Laboratory data is shown in Table 1.
Table 1. Outpatient Laboratory Values
WBC
Hgb
PLT
Sodium
Potassium
Bicarbonate
BUN
Creatinine
Glucose
Total cholesterol
LDL
HDL
TG
CK
Troponin

8.0
15.9
228
138
4.1
25
9
0.8
189
193
113
50
79
321
1.9

The admission chest film showed clear lungs. The ECG,
however, revealed sinus rhythm with ST elevations in
leads II, III, and aVF, as well as ST depressions in the
anterior leads. An echo showed normal chamber sizes,
with distal lateral and mid to distal posterior wall
hypokinesis.
Hospital Course
The patient was admitted to the medical CCU for
management of an ST elevation myocardial infarction,
presumed to be secondary to coronary artery vasospasm.
The vasospasm was attributed to her recent use of
Sumatriptan. She was started on intravenous
nitroglycerin for relief of ongoing chest pain. A
continuous infusion of diltiazem was also started for
control of the vasospasm. Given the patient’s allergy to
aspirin, clopidogrel was initiated. Cardiac enzymes were
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followed and the troponin I peaked at 27 ng/mL. The
patient continued to have episodic chest pain during her
stay in the CCU and consequently four days after her
admission, the patient underwent cardiac catheterization.
Catheterization showed luminal irregularities in the left
main, left anterior descending, left circumflex and right
coronary arteries. The second obtuse marginal, however,
showed 99% occlusion. The left ventriculogram revealed
posterolateral akinesis. Given the tortuosity of the vessel,
the OM2 lesion was not stented. The location of the
occlusion, however, did correspond with the area of
akinesis. It was thought that the patient had underlying
occlusion of the OM2, with superimposed vasospasm
secondary to use of Sumatriptan, and this precipitated
her acute myocardial infarction. The final decision was
to optimize medical management with clopidogrel,
diltiazem and a statin.
Coronary Vasospasm
Coronary vasospasm has also been referred to as
printzmetal or variant angina. Prinzmetal originally
described it in 1959 as a “temporary increased tonus” in
areas of high-grade coronary artery occlusion. Vasospasm
is a syndrome of cardiac pain secondary to myocardial
ischemia. The spasm itself can occur in normal or diseased
vessels and usually occurs within one centimeter of an
atherosclerotic plaque. The resultant ischemia will appear
as ST elevations on ECG, and this can typically be
reversed with nitroglycerine or calcium channel blockers.
The patients suffering coronary vasospasm are commonly
younger than those who present with other forms of
angina. They often lack the cardiovascular risk factors
typically associated with heart disease. As in the above
case, these patients often have other systemic signs and
symptoms of vasospasm, including Raynaud’s
phenomenon and migraine headaches. Interestingly, there
appears to be an increased incidence of symptoms in the
hours between midnight and early morning. The most
common cause of mortality associated with vasospasm
involves arrhythmias, including ventricular tachycardia.
Although the precise mechanisms have not been clearly
defined, there are some circulating theories to explain
the underlying pathogenesis of coronary vasospasm. One
hypothesis involves the autonomic nervous system. It has

been shown that both acetylcholine and methacholine
can precipitate vasospasm, thus inferring that the
parasympathetic nervous system may play a significant
role in the pathogenesis. The discovery that atropine and
alpha-receptor blockers cay prevent such spasm also
supports this theory. In fact, sympathetic denervation
(plexectomy) may be therapeutic in refractory patients.
Endothelial dysfunction may also play a role in
pathogenesis. Decreased levels of the endogenous
vasodilator nitric oxide, and increased levels of the
vasoconstrictor endothelin have been shown to impair
coronary dilatation. These compounds may play an
integral role in coronary vasospasm. Finally, patients with
areas of diffuse intimal thickening of the coronary
vasculature may also be at risk for spasm. With
underlying coronary artery disease, episodic vasospasm
alters preexisting plaques, leading to intimal disruption
and penetration of macrophages or aggregation of
platelets. Consequently, vasospasm may contribute to
vascular instability in these patients.
Sumatriptan, a serotonin (5-hydroxytryptamine [5-HT])
receptor agonist, causes vasoactive constriction of cerebral
vascular beds, making it useful as an abortive therapy for
migraine headaches. However, it has also been shown to
exhibit vasoactive activity in the systemic, coronary, and
pulmonic vascular beds. Three to five percent of patients
experience chest tightness, heaviness, pressure, or pain
after its administration. Occasionally, the chest pressure
or pain radiates to the left arm and hand, imitating angina
pectoris. ECG evidence of myocardial ischemia, however,
is rare. Recently, Welch reported that while over 3 million
migraine attacks have been treated with sumatriptan,
there have only been 4 reported patients with myocardial
ischemia due to coronary vasospasm, 1 of whom also had
cardiac arrhythmia. All four patients had underlying
cardiovascular disease. Sumatriptan has a mild
constrictive effect on coronary arteries. MacIntyre et al
found 10 patients undergoing diagnostic coronary
angiography who had a 14 percent reduction in the
diameter of the coronary arteries. Based on such evidence
and more recent case reports, sumatriptan is
contraindicated in patients with coronary artery disease
or vasospastic angina.
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The typical ECG findings in patients with variant
angina are transient ST elevations associated with chest
pain, that then return to baseline with resolution of
symptoms. Cardiac catheterization plays a major role in
diagnosis. In patients presenting with the typical signs
and symptoms of variant angina, including nonexertional chest pain and ST elevations, angiography
may reveal normal vessels or, as in this case, a proximal
fixed obstruction in one or more of the coronary
arteries. It is in this latter group of patients that
vasospasm should be suspected. Two provocative tests
can help confirm this condition. The most sensitive and
specific test involves injection of intravenous
ergonavine, a vasoconstrictor, during catheterization.
The test is positive if drug administration replicates
symptoms or ECG findings. The effects should be
reversed with intracoronary nitroglycerine. Ergonavine
can also be used in conjunction with echocardiography.
Wall motion abnormalities after injection indicate a
positive test. Hyperventilation is a less sensitive test that
can also be performed during coronary catheterization.
The patient is instructed to hyperventilate for six
minutes and if acute ST changes are seen on ECG,
coronary vasospasm is inferred.
The image below shows cardiac catheterization with
hyperventilation-induced vasospasm of the proximal left
circumflex artery that resolved with the administration
of intracoronary nitroglycerine and diltiazem.
As with all types of coronary artery disease, risk factor
modification is essential. Cessation of smoking must be
enforced. Medical management includes lipid-lowering
medications, and calcium channel blockers or nitrates to
maintain coronary vasodilatory effects. Medical
treatment has shown favorable responses in female
patients and patients with ST-segment elevation during
selective spasm provocation tests. However, patients with
either a longer history of episodic chest pain or a history
of diffuse spasms do not improve with medical treatment
alone. Nonselective beta-blockers should be avoided, as
they may exacerbate vasospasm. Angioplasty is helpful if
there is a discrete area of occlusion, however its utility is
limited by the fact that many patients have multivessel
spasms. It has been recommended that calcium channel
blockers be continued after percutaneous revascularization for this very reason. In refractory patients, surgical
denervation with plexectomy may be an option.
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